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Abstract 
Objectives:  To present baseline characteristics of American Indians in the Stop Athero-
sclerosis in Native Diabetics Study (SANDS) and compare them with population-based 
data from American Indians and other ethnic groups. Design:  499 people with type 
2 diabetes ≥ age 40, without known CVD, were recruited for a randomized 3-year trial 
to evaluate treatment targets for LDL-C (70 vs. 100 mg/dL) and systolic blood pressure 
(BP) (115 vs. 130 mmHg).  Baseline evaluations included physical exam, collection of 
blood and urine samples, and carotid ultrasound and echocardiographic measures. 
Results:  Mean age was 56 years; 66% were female.  Average BMI was 33 kg/m2.  Aver-
age duration of both hypertension and diabetes was 10 years, average A1c was 8.0 %, 
and mean LDL-C was 104 mg/dL.  Participants in the conventional treatment group 
had slightly higher systolic BPs than participants in the aggressive treatment group 
(133 mm Hg vs. 128 mm Hg, p < 0.002).  Compared with the population-based cohorts 
of the Strong Heart Study (SHS), NHANES, and the TRIAD registry, SANDS participants 
had similar values for lipids, BP, and CRP, as well as degree of obesity, smoking rates, 
and renal function as indicated by estimated glomerular filtration rate.  Conclusions:  
The baseline characteristics of the SANDS cohort are similar to those of a population-
based sample of American Indian diabetic men and women and closely resemble 
diabetic men and women of other ethnic groups.  Results from this study can be used 
to identify appropriate targets for LDL-C and BP lowering in diabetic American Indians 
and diabetic patients in other ethnic groups.  
Key words:  lipids, blood pressure, carotid artery intimal medial thickness, 
cardiovascular disease, American Indians
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INTRODUCTION
The aim of the Stop Atherosclerosis in Native Diabetics Study (SANDS) 
is to determine optimum strategies for cardiovascular disease (CVD) risk 
reduction in people with type 2 diabetes.  SANDS is a randomized, open 
label, 3-year trial comparing the effects of aggressive low-density lipoprotein-
cholesterol (LDL-C) (goal < 70 mg/dL) and blood pressure (BP) (goal < 115/75 
mm Hg) reduction with the standard treatment goals of < 100 mg/dL for 
LDL-C and < 130/85 mm Hg for BP (1).  The primary endpoint is a composite of 
progression of atherosclerosis as measured by common carotid artery intimal 
medial thickness (IMT) and clinical events.  Secondary endpoints include 
other carotid and cardiac ultrasonographic measures. The group treated to 
lower targets had an improvement (decrease) in IMT, whereas the standard 
treatment group had a worsening (increase) in IMT.  There was also a greater 
decrease in left ventricular mass index (LVMI) in the aggressive group.  Few 
CVD events occurred overall, with no intergroup difference (2). 
SANDS was initiated because of the increasing incidence of CVD in 
individuals with diabetes (1, 3 , 4) and the paucity of data on which to 
make evidence-based recommendations for optimal treatment targets for 
dyslipidemia and hypertension, established risk factors for CVD in diabetic 
individuals ( 5, 6, 7).  SANDS is being conducted in American Indians, a 
population with high rates of diabetes and diabetes-related CVD (5).  This is 
the first large, randomized interventional trial among American Indians with 
diabetes to assess CVD prevention strategies.  The final sample, 499 men and 
women without baseline CVD, was randomized over a 15-month period and 
followed for 36 months, ending in July 2007.  
This report describes the baseline characteristics of the 499 participants 
who were randomized into SANDS.  To assess the applicability of the trial 
results to the American Indian population and other populations with 
diabetes, we compared the baseline characteristics of SANDS participants 
with three other groups.  One was a population-based sample of American 
Indians as described by Strong Heart Study (SHS) data.  The second group 
was representative of (8) the general U.S. population with diabetes as 
described in the 1999-2004 National Health and Nutrition Examination 
Survey (NHANES) data (9).  NHANES 1999-2004 was designed to over sample 
Mexican Americans, non-Hispanic blacks, and children and adolescents.  The 
final comparator group was the Translating Research Into Action for Diabetes 
(TRIAD) (10) registry, which examined racial/ethnic and socioeconomic 
variation in diabetes care in managed-care settings throughout the United 
States.  The TRIAD cohort included five ethnic groups, Hispanic, Black/
Non-Hispanic, White/Non-Hispanic, Asian/Pacific Islander, and Other.  The 
proportion of White/Non-Hispanic was more than twice than that of each of 
the other groups. 
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METHODS
Details of the study design and methods have been described elsewhere 
(5).  The target population consisted of American Indians in four clinical centers 
in the United States:  Lawton, OK; Phoenix, AZ; Chinle, AZ; and Rapid City, SD.  
Recruitment was initiated in May 2003.  Each center developed community-
specific recruitment plans that included informational mailings, community 
presentations, and referrals from local providers.  Informed consent was 
obtained from all participants before screening, and the study was approved 
by the institutional review boards (IRBs) of all participating institutions and 
the Indian Health Service and by all participating tribal communities.  At least 
one screening visit and a separate randomization visit were required to assess 
and confirm eligibility, complete randomization, and collect baseline data.  
Sonogram eligibility, defined as having adequate images for measurement of 
intimal-medial thickness, was required prior to randomization.   
Eligibility criteria included age ≥ 40 years, type 2 diabetes documented by 
medical record, LDL-C > 100 mg/dL, and systolic BP > 130/85 mm Hg.  Because 
lipid and BP measurements are variable, up to four screening visits within a 
3-month period were allowed to confirm eligibility. Those taking BP or lipid 
lowering medications with elevations in systolic BP or LDL-C documented in 
the medical record were admitted at the discretion of the field physician if it 
was felt that the participant could safely adhere to the study algorithms.  Major 
exclusions included medical conditions that would preclude participation in a 
3-year trial or a history of serious adverse effects from the major study drugs.  
Participants with prevalent CVD were randomized during the early months 
of recruitment.  After release of the National Cholesterol Education Program - 
Adult Treatment Panel III (NCEP-ATP III) (11) guidelines, which recommended an 
LDL-C treatment goal of 70 mg/dL for patients with CVD and other risk factors, 
such as diabetes, the steering committee determined, and the Data and Safety 
Monitoring Board (DSMB) concurred, that all participants with clinical CVD 
would be treated to an LDL-C goal of 70 mg/dL and removed from the primary 
analysis.  Randomization concluded in September 2004 with 548 participants, 
499 of whom had no prevalent CVD.
Physical Measures
Anthropometric measurements were performed using standardized 
methods, with the participant fasting and having an empty bladder, and 
included height, waist circumference measured to the nearest quarter inch and 
weight measured to the nearest tenth pound.  Sitting BP was measured on the 
right brachial artery, and the mean of the second and third measurements was 
used.  Behavioral risk factors were assessed using standardized interviewer-
administered questionnaires, and medical history and medication assessment 
were performed by both interview and chart review.  Clinic staff were certified 
in all measurements and interviews, and quality control was maintained 
through periodic monitoring of duplicate measures and data entry.
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Laboratory Measures
Blood and urine samples were collected after a 12-hr overnight fast, 
and plasma and serum samples were shipped to the core lab (Penn Medical 
Lab).  All samples were shipped and stored at -70º C.  Baseline measurements 
included fasting glucose, complete metabolic profile, A1c, C-reactive protein 
(CRP), lipid profile, and urine for creatinine, albumin, and sodium.  Details of 
assay standardization and quality control have been described elsewhere (5).
Carotid Ultrasound and Echocardiographic Measures 
Carotid ultrasound and echocardiographic studies were obtained at 
baseline before randomization.  All ultrasound studies were performed using 
standardized protocols developed and refined by the Ultrasound Reading 
Center at Weill Medical College of Cornell University in New York (12).  Skilled 
physician-readers blinded to participant characteristics interpreted all 
studies.  Extensive B-mode imaging from multiple angles was performed to 
determine the presence and location of plaque, defined as the presence of 
focal protrusion at least 50% greater than the surrounding wall thickness 
(13).  Pulsed Doppler sampling of the common carotid artery (CCA), carotid 
bifurcation, and internal and external carotid arteries was performed 
to quantify the presence of significant obstruction (14).  The procedure 
was repeated on the contralateral artery.  Plaque severity was graded as 
obstructive (> 50% occlusion based on peak Doppler systolic velocity) or 
non-obstructive.  A plaque score (0-8) was determined based on the number 
of segments of each carotid artery containing plaque (15).  IMT of the far wall 
of the distal left and right common carotid arteries 1-2 cm proximal to the 
carotid bifurcation was measured at end diastole using a semi-automated 
system, which averages 100 individual measurements over a 1-cm length of 
the vessel.  Right and left IMTs were averaged. Vascular mass of the arteries 
was calculated as cross-sectional area, using end-diastolic diameter and wall 
thickness.
Echocardiographic performance and interpretation adhered to published 
methods (16, 17).  Briefly, participants were examined in a partial left 
decubitus position, using phased-array echocardiographs.  Attention was paid 
to correct orientation of imaging planes.  The entire study was recorded on 
videotape and sent to the Reading Center for interpretation.  Left ventricular 
end-diastolic and end-systolic wall thicknesses and diameters were measured 
from parasternal images using American Society of Echocardiography 
recommendations (18 ,19).  Derived variables from these linear measurements 
included assessment of left ventricular structure (mass and relative wall 
thickness) and function (fractional shortening and ejection fraction [EF]).  The 
location and severity of segmental wall motion abnormalities were noted.  
Data Management and Analysis
Data collected in the field center were entered by staff certified in using 
a web-based system developed by the Data Coordinating Center (DCC).  
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Laboratory and ultrasound data were transmitted electronically to the 
DCC.  The central database was maintained using standardized methods for 
ensuring security and verifying accuracy and consistency. 
This paper presents descriptive statistics for all variables of interest in the 
form of means and standard deviations for continuous variables and number 
of observations and percentages for categorical variables.  In addition, 
two-sample comparisons are provided to examine if there are significant 
differences between the conventional and aggressive groups.  Differences in 
the means are tested using two-sample t-tests for means, and differences in 
the proportions are tested using two-sample tests of proportions.  Positively 
skewed variables such as carotid measures, CRP, and triglyceride levels 
are log-transformed prior to the application of the two-sample tests, and 
geometric means or medians and inter-quartile ranges are presented for 
these variables.
RESULTS
Demographic and Physical Characteristics
Of the 1097 men and women who underwent screening, 548 were 
randomized into the trial.  Forty-nine with documented CVD at baseline 
were excluded based on the recommendation of the DSMB, leaving 499 
participants (Table 1).  Mean age was 56 years; 66% were women.  A large 
proportion (66%) was obese, with an average BMI of 33 kg/m2 in both 
men and women (Table 1).  Average duration of diabetes was 10 years.  No 
significant differences were found in baseline characteristics between the 
treatment groups, other than slightly higher systolic BP in the conventional 
treatment group (133 vs. 128 mm Hg, p < .002) and age (56.9 years vs. 55.3 
years, p = 0.05).  No significant differences were found between the groups 
in baseline laboratory measures (Table 2).  Serum LDL-C averaged 104 mg/
dL in both groups.  A1c averaged 8.0 %.  Less than 1% had macroalbuminuria, 
defined as urine albumin/creatinine > 300 mg/g.
Baseline Medications
Baseline medication usage is listed in Table 3.  Seventy-three percent 
of the cohort took anti-hypertensive medications at baseline; angiotensin 
converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARB) were 
used by 64%, with no other single agent used by more than 21%.  Only 38% 
of participants were taking a lipid-lowering agent at baseline.  Statins were 
the most commonly used lipid-lowering agents (34%), while fibrates were 
used by 5%.  Ezetimibe was not readily available at the time of randomization.  
Sixteen percent of participants took no anti-diabetic agent at baseline.  Most 
participants took oral medications only for diabetes (61%), with 6% using 
insulin only and 17% using both.
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Cardiovascular Measures
Carotid IMT and mass and presence and extent of carotid atherosclerosis 
(Table 4) were similar between the two groups.  Echocardiographic measures 
of LV structure and function were also similar between the groups.
Table 1.  Baseline Characteristics of Participants Without CVD at 
Baseline
Analysis Variables Conventional Aggressive P-value*
Participants (N) 247 252
Female 160 (64.8) 167 (66.3) .73
Age at randomization (yrs) 56.9 (8.9) 55.3 (9.3) .05
SBP (mm Hg) 133 (16.6) 128 (14.9) .002
DBP (mm Hg) 76 (10.4) 74.4 (10.3) .04
Duration of  hypertension (yrs) 10.4 (8.5) 9.4 (8.2) .26
Duration of diabetes (yrs) 9.6 (8.1) 9.8 (7.6) .82
BMI (kg/m2) Men 32.8 (5.5) 33.5 (6.4) .44
BMI (kg/m2)  Women 33.4 (6.5) 33.5 (6.7) .88
BMI (kg/m2) < 30 75 (30.5) 80 (31.8) .74
BMI (kg/m2) > 30 172 (69.5) 172 (68.2) .74
Total daily calories (Kcal) 2098 (1547) 1880 (1190) .15
Waist circumference (cm) Men 111.4 (13.4) 113.1 (16.1) .45
Waist circumference (cm) Women 109.3 (14.3) 108.8 (14.9) .74
Smoking status (N) 244 243
     Never 123 (51) 109 (45) .20
     Current 48 (20) 54 (22) .58
     Former 73 (30) 80 (33) .60
SBP = systolic blood pressure; DBP = diastolic blood pressure.  Percentages 
may not add up to 100 because of rounding.  Data presented in this table 
are means with standard deviations in parentheses for continuous variables 
and N and percentages for categorical variables.
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Comparison with Population-Based Data
Compared with the population-based cohort of American Indians in 
the SHS (7), SANDS participants had similar values for lipids, BP, and CRP, as 
well as degree of obesity, smoking rates, and renal function as estimated 
by glomerular filtration rate (GFR) (Table 5).  The SANDS cohort was slightly 
younger, with a shorter duration of diabetes, but average A1c was similar.  
Compared with men and women with diabetes in NHANES (9), SANDS 
participants were slightly younger with slightly shorter diabetes duration 
and slightly higher A1cs.  BPs in the two groups were similar.  LDL-C, high 
density lipoprotein cholesterol (HDL-C), and triglycerides (TG) were lower 
among the SANDS participants, but smoking rates were similar.  Compared 
with participants in TRIAD, SANDS participants were somewhat younger, more 
likely to be female, and had somewhat lower mean systolic BP and LDL-C. 
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Table 2.  Baseline Laboratory Values by Treatment Group
Analysis Variables Conventional Aggressive P-value*
Fasting glucose (mg/dL) (SD) 156.5 (71.1) 159.3 (69.3) .66
CRP* (95% CI) 2.84 (2.43-3.31)
2.66 (2.27-
3.11) .56
Serum creatinine (mg/dL) (SD) 0.85 (0.2) 0.83 (0.2) .34
Cholesterol (mg/dL) (SD)
Total 185 (33) 184 (33) .56
LDL 104 (29) 104 (30) .95
HDL 46 (12) 46 (13) .90
Non-HDL 140 (32) 138 (32) 0.50
Triglycerides (mg/dL)* (95% CI) 168 (159-177) 158 (149-167) .10
Microalbumin/creatinine ratio (urine)
(N) % normal (< 30 mg/g) (139) 87 (148) 94 .09
(N) % with micro-albuminuria 
(30-300 mg/g) (19) 12 (14) 5
Estimated GFR (MDRD)
 Mean  (SD) 88.2 (23.3) 90.9 (24.1) .21
(N) % < 60 ml/min (18) 11.1 (3) 9.3 .51
Urinary sodium (mmol/L) (SD) 99.4 (50.6) 98.3 (48.2) .84
CRP = C-reactive protein; GFR = glomerular filtration rate; MDRD = Modification of Diet 
in Renal Disease. *Geometric mean with 95% confidence interval in parenthesis.  Two-
sample comparison t-tests are calculated based on log-transformed variables.
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Table 3.  Baseline Medication Use 
Conventional (%) Aggressive (%) P-value*
N 242 252
Anti-hypertensive
ACE inhibitor/ARB 155 (63) 163 (65) .65
Thiazide diuretic 29 (12) 20 (8) .15
Beta blocker 24 (10) 19 (8) .38
Calcium blocker 48 (20) 43 (17) .48
Other anti HTN rx 56 (23) 50 (20) .43
Any 185 (75) 179 (71) .28
Lipid lowering
Statin 90 (37) 80 (32) .26
Fibrate 13 (5) 12 (5) .48
Ezetimibe 2 (0.8) 1 (0.4) .49
Any 101 (41) 90 (36) .23
Diabetes
Insulin only 12 (5) 18 (7) .28
Oral agent only 145 (59) 158 (63) .62
Both (oral and insulin) 38 (15) 48 (19) .28
Lifestyle only 52 (21) 28 (11) .003
Aspirin 89 (36) 77 (31) .18
Entries are numbers of observations; percentages are in parentheses.
Table  4.  Echocardiographic and Carotid Measures
Conventional Aggressive P-value
CCA IMT (mm) * .78 (.68-.87) .78(.69-.90) .48**
CCA mass (mm2)* 16.7 (14.2-19.4) 16.6(13.9-19.5) .99**
Plaque (%) *** 76 75 .64
Plaque score 2(1-3) 2 (0-3) .89**
LV ejection fraction (%) 59.8 (5.8) 60.5 (5.7) .19
LV mass (g) 156.1 (38.3) 156.7 (38.3) .86
LV mass index (g/m2.7) 40.6 (8.5) 41.2 (9.5) .43
% LVH men, > 49.2/m2.7 *** 14 22 .15
% LVH  women , 
> 46.7 g/m2.7 *** 23 30 .14
*Medians and inter-quartile ranges (observations between 25th and 75th percentile) 
are provided for positively skewed variables.  **p-values represent the results of 
two-sample means tests applied to the log-transformed continuous variables. The 
descriptive statistics for these continuous variables are based on actual values.            
*** indicates categorical variables. The entries in the means columns for these 
variables are percentages within each group. P-values are based on two-sample tests 
of proportions.
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N 499 1733 1549 3707
Male (%) 172 (34) 590 (34) 759 (49) 1838 (50)
Female (%) 327 (66) 1143 (66) 790 (51) 1869 (50)
Age (yrs) (SD) 56 (9.0) 63 (7) 59 (0.5) 62 (13)
BMI (kg/m2)
  Men (SD) 33.1 (6.0) 31.4
  Women (SD) 33.5 (6.6) 33.3
  Men and women 33.3 32.7 31.8 31.5
HTN duration (yrs) 9.9 (8.3) 8.0
SBP (mmHg) 130.4 (15.9) 132 (20.2) 132 (0.8) 136 (19.0)
DBP (mmHg) 75.3 (10.4) 75 (29.7) 69 (0.72) 76 (11.0)
Diabetes duration 
(yrs) 9.7 (7.8) 15.7 (12.2) 12.0 (0.5)
A1c (%) (SD) 8.0 (1.8) 8.1 (1.9) 7.5 (0.2) 7.8 (1.7)
Total cholesterol 
(mg/dL) (SD) 184 182 (39) 205(2) 196 (43)
LDL-C (mg/dL) (SD) 104 110 (32) 115 (2) 110 (33)
HDL-C (mg/dL) (SD) 46 40 (12) 47 (1) 46 (13)
Non-HDL-C (mg/dL) 
(SD) 139 (32) 142 (39) 196 (9) 151 (42)
TG (mg/dL) (SD) 163 (geo mean) 162 (122)
220 
(187)








Smoking (% ever) 52.3 58.8 53.2 49
Mean IMT (mm) 0.80 ± 0.18 0.75 ± 0.16
Mean CCA mass 
(mm2) 17.3 ± 4.8 16.5 ± 4.5
Plaque (%) 76 67
Plaque score (n) 1.8 ± 1.6 1.7 ± 1.7
LVMI (g/m2.7) 40.9 (9.0) 40.4 (10.0)
*The NHANES cohort excluded people who were pregnant or on dialysis. **The TRIAD 
cohort  was white, non-Hispanic.  HTN = hypertension; SBP = systolic blood pressure; 
DBP = diastolic blood pressure; LDL-C = low-density lipoprotein-cholesterol; HDL-C = 
high-density lipoprotein-cholesterol; TG = triglycerides; eGFR = estimated glomerular 
filtration rate; NA = not applicable.
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DISCUSSION
Baseline BP levels in the SANDS participants were within the normal 
range, probably due to the use of antihypertension medications by over 70%.  
Of note, average BP levels in American Indians are lower than those in other 
U.S. populations and, even in those with diabetes, stage III or IV hypertension 
is rare (20).  Nevertheless, BP is a strong predictor of CVD events in American 
Indians (20), even in those with pre-hypertension (21).  Thus, it was postulated 
that risk would be considerably reduced with the intensive intervention.
Lipid levels are also low in this cohort, with a mean LDL-C of 104 mg/dL.  
Only 38% were taking statins or other hypolipidemic medication at baseline.  
LDL-C levels are lower among American Indians than in the general U.S. 
population and are slightly lower in diabetic than in non-diabetic individuals 
(22).  Despite a relatively low mean level, LDL-C is the strongest lipid predictor 
of CVD in American Indians with diabetes; a 10-mg/dL increase in LDL-C is 
associated with a 12% increase in CVD risk (23).  These data indicate that 
LDL-C has a particularly strong impact on CVD in this population, suggesting 
that the lower therapeutic target will be effective.
Carotid artery IMT is a widely accepted surrogate marker for 
atherosclerosis and is strongly associated with major CVD risk factors (24) 
and prevalent and incident CVD (25).  Diabetes is associated with increased 
IMT (26,27 ).  In other diabetic populations, carotid IMT predicted CVD and 
correlated with CVD risk factors, such as diabetes (28).  Plaque and plaque 
score are independent predictors of incident CVD events in American 
Indians without pre-existing CVD.  All four measures of sub-clinical carotid 
atherosclerosis in SANDS were slightly higher compared with the diabetic SHS 
participants studied a mean of 6 years earlier (Table 5), suggesting that sub-
clinical disease among American Indians may be increasing, despite lower 
mean LDL-C and BP levels.  Thus, differences in these surrogate measures 
in the aggressive and conventional therapy groups at the conclusion of the 
study may predict differences in the occurrence of CVD events in the two 
groups
Left ventricular hypertrophy (LVH) is a strong, independent risk indicator 
for CVD events.  Reversal of LVH has prognostic benefit, independent 
of therapy and BP (28).  Diabetes has been shown to be independently 
associated with greater absolute and relative LV wall thicknesses (but 
not larger chamber size) and with higher absolute and indexed LV mass 
independent of all confounders (17).  Absolute LV mass, or LV mass indexed 
for measures of body size, was virtually identical in SANDS (41.0 gm/
m2.7, SD 9.2) and SHS participants with diabetes (40.4 gm/m2.7, SD 10.0) 
(29).  Echocardiographic structural and functional abnormalities are highly 
prevalent among American Indians with diabetes and appear to be predictors 
of clinical CVD events.  In a regression analysis that considered other 
predictors of mortality, cardiovascular death in diabetic SHS participants was 
most strongly predicted by higher LV mass/height2.7 (p = 0.0001) (30).  When 
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analyses were restricted to participants with diabetes, all-cause mortality, 
cardiovascular death, and nonfatal cardiovascular events were all more 
common in those with LV hypertrophy (28).  Thus, SANDS will have the added 
benefit of determining whether several abnormalities in cardiac structure and 
function also improve with risk-factor modification, an issue not previously 
addressed in any diabetes trials.
The SANDS cohort consisted of trial volunteers and thus is subject 
to the healthy volunteer bias in clinical trial participants.  Additionally, 
individuals with CVD and renal failure were excluded from SANDS but not 
SHS.  Thus, it was important to determine to what extent the SANDS cohort 
is representative of other diabetic groups.  The baseline characteristics of the 
SANDS cohort are similar to those of the American Indian diabetic population 
from the Strong Heart Study and also resemble diabetic men and women 
of other ethnic groups.  Although blood pressure and LDL-C in the SANDS 
cohort are not high, the carotid ultrasound and echocardiographic findings 
show much evidence of preclinical disease. 
Traditional goals for blood pressure (< 130/80 mmHg) and LDL-C (< 
100 mg/dL) for high-risk patients may be inadequate to reduce CVD risk in 
American Indians and other diabetic populations at high risk for CVD.  The 
data obtained in this study have provided evidence to define therapeutic 
prevention strategies that can reverse the alarming increase in CVD among 
American Indians with diabetes and will guide treatment strategies for 
diabetic individuals from all U.S. ethnic groups and in other countries where 
diabetes rates are rising.
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